By Paul Hoskins and Ben Hirschler DUBLIN/LONDON (Reuters) - Shares in Irish drugmaker Elan Corp PLC ELN lost half their value on Friday while partner Biogen Idec tumbled 25 percent as renewed safety concerns call into question the future of their multiple sclerosis...
By Deena Beasley and Bill Berkrot LOS ANGELES/NEW YORK (Reuters UK) - Biogen Idec BIIB and Elan ELN have notified regulators of two new cases of a potentially deadly brain disease in multiple sclerosis MS patients being treated with Tysabri. Biogen shares dropped about 23 percent...
CAMBRIDGE, Mass. & DUBLIN, Ireland -- Biogen Idec Inc.(NASDAQ: BIIB) and Elan (NYSE: ELN) today announced it will host a conference call for the Investment Community to discuss the recent events related to TYSABRI([R])natalizumab on Friday, August 1, 2008 at 8:30 a.m. ET/1:30 pm British Summer Time BST. ...
DUBLIN, Ireland -- Elan Corporation, plc today announced its second quarter 2008 financial results and provided a business update. Commenting on Elan's business, Kelly Martin, Elan's president and chief executive officer, said, "Disciplined execution and tangible results for the benefit of patients and shareholders continue to be our enduring tenet....
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/c65118/biogen_idec_inc) has announced the addition of the "Biogen Idec Inc.: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy,...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/2b1eee/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis: Gastrointestinal Disorders -- UC, Crohn's, OIC, GERD" report to their offering. This report provides in-depth analysis of the market and pipeline from the perspective of global thought...
One of the first pills to treat the "relapse-remitting" form of multiple sclerosis has been shown to help fight the disease with few side effects. Although the drug, laquinimod, is still experimental, having a pill available would make therapy much more convenient for many patients. "By and large, this...
PALO ALTO, Calif. -- The U.S. therapeutic monoclonal antibodies market is poised for a quantum leap with the launch of a multitude of new products and vigorous expansion of therapeutic indications of existing products. A combination of these factors, along with high demand and lack of generic...
Commissioner von Eschenbach told an April Senate hearing his agency could easily absorb an extra $100 million for FY 2009 to beef up medical product and food safety operations. However, he said, FDA could not responsibly absorb in one year the $375 million that its Science Board advised. ...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reportinfo.asp?report_id=461212) has announced the addition of "Therapeutic Clinical Intelligence-Inflammatory Bowel Disease" to their offering. This report is a competitive intelligence on the clinical trials of products on the market and in the development for Crohn's Disease & Ulcerative Colitis. Crohn's...
DUBLIN, Ireland -- Elan Corporation, plc today announced its first quarter 2008 financial results and provided a business update. Commenting on Elan's business, Kelly Martin, Elan's president and chief executive officer, said, "We continued to demonstrate successful execution and delivery of tangible results in the first quarter. We remain highly...
-- 32% Revenue Growth -- CAMBRIDGE, Mass. -- Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today reported its first quarter 2008 results. First Quarter 2008 Highlights: * First quarter revenues were $942...
CHICAGO -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced additional findings from the PLEX study which shows that plasma exchange accelerates the removal of TYSABRI([R]) natalizumab from blood serum in patients and may help improve central nervous system immune response based on an in vitro...
-- Approximately 26,000 Patients on Commercial and Clinical Therapy Worldwide -- -- Additional Analyses Show TYSABRI Significantly Increased the Proportion of Multiple Sclerosis MS Patients Who are Considered Disease Free for Over Two Years -- CHICAGO -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE:...
CHICAGO -- Biogen Idec (NASDAQ: BIIB) today announced that 17 company-sponsored plenary sessions, platform presentations, and poster presentations will be presented during the 60th Annual Meeting of the American Academy of Neurology. These presentations will cover four compounds that are marketed or currently in development by Biogen Idec and its...
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Biogen Idec, Inc. (Nasdaq: BIIB), Pfizer (NYSE: PFE), Wyeth (NYSE: WYE),...
The controversial multiple sclerosis drug Tysabri can start causing liver damage within six days of the first dose, U.S. health officials said Wednesday. In January, the U.S. Food and Drug Administration expanded the use of Tysabri to treat Crohn's disease, a chronic inflammation of the digestive tract. The drug has...
DUBLIN, Ireland -- Elan Corporation, plc today announced its full-year and fourth quarter 2007 financial results and provided guidance for its financial outlook for 2008. Commenting on Elan's business, Kelly Martin, Elan's president and chief executive officer, said, "Our key operating principles of patient focus, disciplined execution, and delivery of...
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Biogen Idec (Nasdaq: BIIB), Pfizer (NYSE: PFE), Wyeth (NYSE: WYE), AstraZeneca...
CAMBRIDGE, Mass. -- Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today reported its full year and fourth quarter 2007 results. Full Year 2007 Highlights: * Total revenues in 2007 were $3.17 billion, an increase...
Articles 2008-02-06
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
